biologic

Xeomin

incobotulinumtoxinA

Loss of exclusivityNovember 2027projected — 12-year biologic exclusivity estimate
CompanyMerz Pharmaceuticals GmbH c/o Merz Pharmaceuticals LLC

Drug detail

Brand nameXeomin
Active ingredientincobotulinumtoxinA
Strength200UNITS
Dosage formFor Injection
RouteIntramuscular, Intraglandular
ModalityBiologic
FDA approvalNovember 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found